Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up

JAMA

Volumn 280, Issue 1, 1998, Pages 35-41

  Gulick, Roy M ^a,f   Mellors, John W ^b   Havlir, Diane ^c   Eron, Joseph J ^d   Gonzalez, Charles ^a   McMahon, Deborah ^b   Jonas, Leslie ^e   Meibohm, Anne ^e   Holder, Daniel ^e   Schleif, William A ^e   Condra, Jon H ^e   Emini, Emilio A ^e   Isaacs, Robin ^e   Chodakewitz, Jeffrey A ^e   Richman, Douglas D ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Cornell University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS INHIBITION;

EID: 0032122438     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.1.35     Document Type: Article

References (30)

1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
2. Montaner JSG, Reiss P, Cooper D, et al, for the INCAS Study Group. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA. 1998;279:930-937.
3. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1997;277:1962-1969.
4. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 1998; 47(RR-05):43-82.
5. Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologic failure to indinavir or/and ritonavir in an urban health clinic. Paper presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28, 1997; Toronto, Ontario. Abstract LB-2.
6. Haubrich R, Currier J, Forthal D, et al. Low rate of maximal suppression of HIV-1 RNA in a trial of RNA monitoring in clinical practice. Paper presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28, 1997; Toronto, Ontario. Abstract I-128b.
7. Salit IE, Waring V. Protease inhibitors: use and effects in an HIV clinic. Paper presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28, 1997; Toronto, Ontario. Abstract I-99.
8. Rozenbaum W, Adda N, Wirbel E, Hadacek B, Schneider B, Costagliola D. Predictors and incidence of failure in 500 advanced stage HIV patients treated with indinavir. Paper presented at: Fifth Conference on Retroviruses and Opportunistic Infections; February 3, 1998; Chicago, Ill. Abstract 420.
9. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:8270-8276.
10. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science. 1989;243:1731-1734.
11. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confers high-level resistance to zidovudine. Science. 1989;246:1155-1158.
12. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90: 5653-5656.
13. Schinazi RF, Lloyd RM Jr, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993;37:875-881.
14. Gao Q, Gu Z, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 1993; 37:1390-1392.
15. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998; 72:2422-2428.
16. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.
17. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
18. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996;10:975-981.
19. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995;333:1528-1533.
20. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;333:1534-1539.
21. Connick E, Lederman M, Kotzin B, et al. Immunologic effects of 48 weeks of AZT/3TC/ritonavir. Paper presented at: Fifth Conference on Retroviruses and Opportunistic Infections; February 5, 1998; Chicago, Ill. Abstract LB-14.
22. + T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
23. Buckton KE, Brown WM, Smith PG. Lymphocyte survival in men treated with x-rays for anky-losing spondylitis. Nature. 1967;214:470-473.
24. Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature. 1992;360:264-265.
25. + T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997; 89:3700-3707.
26. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
27. 3-60 week follow-up. Paper presented at: Fifth Conference on Retroviruses and Opportunistic Infections; February 3, 1998; Chicago, Ill. Abstract 383.
28. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278:1291-1295.
29. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
30. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94:13193-13197.